全文获取类型
收费全文 | 2055篇 |
免费 | 0篇 |
专业分类
化学工业 | 9篇 |
金属工艺 | 3篇 |
建筑科学 | 5篇 |
轻工业 | 4篇 |
无线电 | 2篇 |
一般工业技术 | 1篇 |
冶金工业 | 2031篇 |
出版年
2020年 | 3篇 |
2019年 | 2篇 |
2011年 | 1篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2003年 | 7篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1999年 | 57篇 |
1998年 | 621篇 |
1997年 | 363篇 |
1996年 | 217篇 |
1995年 | 151篇 |
1994年 | 108篇 |
1993年 | 134篇 |
1992年 | 21篇 |
1991年 | 33篇 |
1990年 | 29篇 |
1989年 | 30篇 |
1988年 | 25篇 |
1987年 | 22篇 |
1986年 | 23篇 |
1985年 | 24篇 |
1984年 | 1篇 |
1983年 | 4篇 |
1982年 | 8篇 |
1981年 | 14篇 |
1980年 | 20篇 |
1978年 | 4篇 |
1977年 | 45篇 |
1976年 | 82篇 |
1975年 | 1篇 |
1959年 | 1篇 |
排序方式: 共有2055条查询结果,搜索用时 296 毫秒
121.
122.
123.
Noncompliance with medication is common, particularly in asymptomatic conditions such as hypertension that require long-term treatment, and is often unsuspected. We describe two patients with refractory hypertension in whom noncompliance was confirmed by a precipitous fall in blood pressure when antihypertensive medications were given under direct supervision. 相似文献
124.
125.
Replication protein A (RPA) is a trimeric single-stranded DNA-binding protein complex involved in DNA replication, repair, and recombination. DNA damage induces phosphorylation of the RPA p34 subunit, and it has been speculated that this phosphorylation could contribute to the regulation of the DNA damage-induced S-phase checkpoint. To further examine this potential relationship, human cell lines expressing ataxia telangiectasia (AT)-mutated dominant-negative fragments, which fail to arrest in S phase in response to ionizing radiation (IR), and AT cells expressing AT-mutated-complementing fragments, which regain the ability to arrest replicative DNA synthesis in response to IR, were analyzed for radiation-induced RPA phosphorylation. Results from these studies demonstrate that IR-induced RPA phosphorylation can be uncoupled from the S-phase checkpoint, suggesting that RPA phosphorylation in response to IR is neither necessary nor sufficient for an S-phase arrest. 相似文献
126.
127.
128.
Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to pancreatic pro-carboxypeptidase B. Cleavage of the zymogen by thrombin/thrombomodulin generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely modulates fibrinolysis in vivo. In the present work we stably expressed recombinant TAFI in baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium, and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of activation by thrombin/thrombomodulin. Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with kcat = 0.55 s-1, K(m) = 0.54 microM, and Kd = 6.0 nM for rTAFI and kcat = 0.61 s-1, K(m) = 0.55 microM, and Kd = 6.6 nM for pTAFI. The respective TAFIa species also were prepared and compared with respect to thermal stability and enzymatic properties, including inhibition of fibrinolysis. The half-life of both enzymes at 37 degrees C is about 10 min, and the decay of enzymatic activity is associated with a quenching (to approximately 62% of the initial value at 60 min) of the intrinsic fluorescence of the enzyme. Stability was highly temperature-dependent, which, according to transition state theory, indicates both high enthalpy and entropy changes associated with inactivation (delta Ho++ approximately equal to 45 kcal/mol and delta So++ approximately equal to 80 cal/mol/K). Both species of TAFIa are stabilized by the competitive inhibitors 2-guanidinoethylmercaptosuccinic acid and epsilon-aminocaproic acid. rTAFIa and pTAFIa are very similar with respect to kinetics of cleavage of small substrates, susceptibility to inhibitors, and ability to retard both tPA-induced and plasmin-mediated fibrinolysis. These studies provide new insights into the thermal instability of TAFIa, a property which could be a significant regulator of its activity in vivo; in addition, they show that rTAFI and rTAFIa are excellent surrogates for the natural plasma-derived species, a necessary prerequisite for future studies of structure and function by site-specific mutagenesis. 相似文献
129.
MB Elam J Heckman JR Crouse DB Hunninghake JA Herd M Davidson IL Gordon EB Bortey WP Forbes 《Canadian Metallurgical Quarterly》1998,18(12):1942-1947
Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United States for treatment of symptomatic intermittent claudication (IC). Cilostazol has been shown to improve walking distance in patients with IC. In addition to its reported vasodilator and antiplatelet effects, cilostazol has been proposed to have beneficial effects on plasma lipoproteins. We examined the effect of cilostazol versus placebo on plasma lipoproteins in 189 patients with IC. After 12 weeks of therapy with 100 mg cilostazol BID, plasma triglycerides decreased 15% (P<0.001). Cilostazol also increased plasma high density lipoprotein cholesterol (HDL-C) (10%) and apolipoprotein (apo) A1 (5.7%) significantly (P<0.001 and P<0.01, respectively). Both HDL3 and HDL2 subfractions were increased by cilostazol; however, the greatest percentage increase was observed in HDL2. Individuals with baseline hypertriglyceridemia (>140 mg/dL) experienced the greatest changes in both HDL-C and triglycerides with cilostazol treatment. In that subset of patients, HDL-C was increased 12.2% and triglycerides were decreased 23%. With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P<0.002) increase in the apoA1 to apoB ratio. Low density lipoprotein cholesterol and lipoprotein(a) concentrations were unaffected. Cilostazol treatment resulted in a 35% increase in treadmill walking time (P=0.0015) and a 9.03% increase in ankle-brachial index (P<0.001). These results indicate that in addition to improving the symptoms of IC, cilostazol also favorably modifies plasma lipoproteins in patients with peripheral arterial disease. The mechanism of this effect is currently unknown. 相似文献
130.